DVTs & Cancer.

[pjoshea13]

New Danish study below.

"During the first 6months following {upper-extremity deep venous thrombosis}, the absolute risk of any cancer was 5.4%".

This is yet another reminder that cancer & blood clots go together. Having PCa, we must be wary of abnormal clotting activity. A D-dimer test can expose it; nattokinase can dissolve it.

-Patrick

ncbi.nlm.nih.gov/pubmed/292...

Thromb Res. 2017 Nov 22;161:106-110. doi: 10.1016/j.thromres.2017.11.017. [Epub ahead of print]

Risk and prognosis of cancer after upper-extremity deep venous thrombosis: A population-based cohort study.

Adelborg K1, Horváth-Puhó E2, Sundbøll J2, Prandoni P3, Ording A2, Sørensen HT2.

Author information

1

Department of Clinical Epidemiology, Aarhus University Hospital, Denmark. Electronic address: [e-mail].

2

Department of Clinical Epidemiology, Aarhus University Hospital, Denmark.

3

Department of Cardiovascular Sciences, Vascular Medicine Unit, University of Padua, Italy.

Abstract

INTRODUCTION:

The association between lower-extremity venous thrombosis and cancer is well-established. However, the extent to which upper-extremity deep venous thrombosis (U-DVT) is a marker of cancer and a prognostic factor for all-cause mortality remains poorly understood. We examined the risk of cancer after a diagnosis of U-DVT compared with cancer risk in the general population.

MATERIALS AND METHODS:

Using Danish nationwide population-based medical registries, we identified all patients with first-time U-DVT during 1980-1993 and 2000-2013. Cancer incidence was ascertained using data from the Danish Cancer Registry. We computed standardized incidence ratios (SIRs) calculated as the observed number of cancers relative to the expected number based on national incidence rates by sex, age, and calendar year. We created a matched comparison cohort of cancer patients without U-DVT, to assess the impact of U-DVT on all-cause mortality.

RESULTS:

Among 1087 patients with U-DVT, 232 patients subsequently were diagnosed with cancer, corresponding to an overall SIR of 1.69 (95% confidence interval, 1.48-1.92). During the first 6months following U-DVT, the absolute risk of any cancer was 5.4%, corresponding to a 13-fold elevated SIR. During the subsequent 6-12months and >12months, the SIR remained 2-fold and 1.3-fold elevated, respectively. U-DVT was a prognostic factor for all-cause mortality in patients with lung, prostate, and colorectal cancer during the first 6months of follow-up.

CONCLUSION:

U-DVT was a marker of cancer. The clinical utility of searching for occult cancer in patients with U-DVT remains unknown.

Copyright © 2017 Elsevier Ltd. All rights reserved.

KEYWORDS:

Cancer; Deep vein thrombosis; Epidemiological studies

PMID: 29245061 DOI: 10.1016/j.thromres.2017.11.017